




5th Microbiome R&D and Business Collaboration Forum: USA

COLLABORATIONS IN MICROBIOME RESEARCH, LIVE BACTERIAL THERAPEUTICS, HUMAN HEALTH & DISEASE

2nd Probiotics Congress: USA

IDENTIFICATION, DEVELOPMENT & DELIVERY OF PROBIOTICS AND PREBIOTICS IN HUMAN HEALTH

Global Engage is pleased to announce, as part of their worldwide microbiome series, the 5th U.S. Microbiome R&D and Business Collaboration Forum and co-located 2nd Probiotics Congress which will be held on November 2-3, 2017 in San Diego. The congress which attracted over 350 attendees in 2016 is the sister meeting to both the European and Asian Congresses held in Amsterdam and Hong Kong which bring together an even-split of industry and academic delegates to discuss the latest microbiome science, the development of partnerships and commercial collaborations in this area and the growth of product pipelines.

An increasing awareness of the importance of the role different bacterial ecosystems play with regards to human and animal health has led to a surge in research, publications and companies coming out of the microbiome and probiotic space. As changes in our lifestyle and the growth of multi-drug resistant bacterial strains have also increased the need for better solutions and management of chronic and life-threatening illnesses, microbiome and probiotic research is one of the most scientifically important and potentially lucrative avenues to be exploring. There is mounting evidence that selected probiotic strains can confer health benefits to us especially in digestive diseases and paediatric health and the first microbiome-based drugs will be headed to market in the next few years.

Attracting over 400 attendees, the 12th meeting in the global series will build upon the success of last year's meeting as well as our highly popular European and Asia forums to explore the interface between our evolving cultures, technologies and our microbiome through a series of interactive presentations with leading academics and industry experts, panel discussions, roundtable discussions and an exhibition area allowing solution providers to showcase their products and services. The Global Engage series is rapidly gaining a fantastic reputation as the number one microbiome networking event for fostering partnerships across academia, pharma and biotech. If looking to either learn more from the top scientists in the microbiome and probiotic space; showcase exciting developments in your research; or seek partnerships and funding within the industry; it is a congress not to be missed!

Conference Overview

Summary:

- +50 presentations from industry and academic leaders
- +7 hours of dedicated networking time
- 7 expert-led roundtable discussions
- 3 extended senior-level interactive panel discussions
- Showcasing the latest start-ups
- Fall sun in beautiful San Diego

Gut Microbiome

- Gut microbiome in health and disease
- Pharma and biotech drug development – bugs as drugs
- Microbiome and cancer
- Interventions in the microbiome – probiotics/phage/FMT/synthetic biology
- Research in obesity, cardio-metabolic disease, IBD, MS, allergy, metabolic disease, autoimmune disorders & more
- Utilizing microbiome data sets

Outside the Gut

- Skin microbiome - acne, eczema, atopic dermatitis, probiotics, wound health & cosmetic applications
- Women's health – host-interactions, vaginal microbiome, preterm birth and pregnancy progression
- Gut-brain axis – signalling, links to disease and behaviour
- Oral and respiratory microbiome research

Commercialization of the Microbiome

- Venture capital and funding options
- Pharma and biotech case studies and strategies
- Partnering across the microbiome field – industry/academia
- Development, application & acquisition of technology platforms within the microbiome space
- Regulatory compliance
- Intellectual property considerations and protection
- Drug target validation and candidate selection
- Preclinical modelling
- Translational research
- How to develop microbiome start-ups
- Consumer markets v therapeutic markets

Probiotics and Prebiotics

- Probiotics and digestive health
- Probiotics in paediatrics
- Regulation and product development
- Strain identification, screenings and safety
- Delivery methods and encapsulation
- Regulatory considerations and quality control
- Case studies of pro- and prebiotic effects on human health
- Role of human milk oligosaccharides
- Commercializing pro- and prebiotic research

Confirmed Speakers and Chairs



Rob Knight
Professor of Pediatrics and
Computer Science & Engineering,
University of California, San Diego
(Reserved)



Timothy Lu
Associate Professor in the
Department of Electrical
Engineering and Computer Science,
MIT



Sarkis Mazmanian
Louis & Nelly Soux Professor of
Microbiology, California Institute
of Technology



Jenny Kim
Professor of Clinical Medicine,
University of California, Los
Angeles



Wenyuan Shi
Professor and Chair of Oral Biology,
UCLA Schools of Medicine and
Dentistry/CSO, C3 Jian Inc.



Yuying Liu
Associate Professor, Department of
Pediatrics, University of Texas



Lee Jones
Founder, President & CEO,
Rebiotix




Anurag Pande
Vice President – Scientific Affairs
Sabinsa Corporation



Susan Smith
Head of Immunology, Dermatology
Therapy Area, GlaxoSmithKline



Jorge Frias-Lopez
Associate Professor, Department
of Oral Biology, University of
Florida



Lada Rasochova
Chief Executive Officer, Dermata
Inc. [SESSION CHAIR]



Lee Madsen II
Vice President & Chief Science
Officer, ISOThrive



Jasmina Aganovic
President, Mother Dirt



Sergio Baranzini
Professor, Department of
Neurology, University of California,
San Francisco



Trevor Steyn
Chief Executive Officer, ESSE
Probiotic Skincare



Tiffany Weir
Associate Professor, Colorado
State University



Thomas Hitchcock
Founder and Chief Executive
Officer, Xycrobe Therapeutics Inc.



Marina Walther-Antonio
Assistant Professor of Surgery,
College of Medicine, Mayo Clinic



Mohan S. Iyer
Chief Business Officer,
Second Genome



Mary Ellen Sanders
Executive Science Officer,
International Scientific Association
for Probiotics and Prebiotics



Joy Scaria
Assistant Professor, Department of
Veterinary & Biomedical Sciences,



Ulrich Kulozik
Professor & Chair of Food Process
Engineering and Dairy Science,
Technical University of Munich,
Germany




Henry Rath
Vice President, Business
Development and Strategy, Seres
Therapeutics



Malcolm Kendall
Co-Founder & CEO, Microbiome
Insights, Inc.



Mark Smith
Chief Executive Officer, Finch
Therapeutics



Adela Cardones
Assistant Professor of Dermatology,
Duke University



Buffy Stahl
Genomics and Microbiome Science
Leader, DuPont Nutrition & Health



Peter Lee
Founder & Executive Chairman,
Osel inc.



Jackie Papkoff
Senior Vice President Research,
Evelo Biosciences



Jan Peter van Pijkeren
Assistant Professor, Department of
Food Science, University of
Wisconsin-Madison



Lata Jayaraman
Senior Director,
Seres Therapeutics



Erik Spek
Vice President – Head of
Intellectual Property, Vedanta
Biosciences



Paul Cotter
Head of Department, Food
Biosciences, Teagasc, Republic of
Ireland



Colleen Cutcliffe
CEO & Co-Founder,
Whole Biome Inc.



Emma Taylor
Chief Executive Officer & Co-
Founder, Naked Biome



Michael Bailey
Associate Professor, Pediatrics, The
Ohio State University

Confirmed Speakers and Chairs continued...



Sonia Michail
Professor of Clinical Pediatrics,
University of Southern California



David Donabedian
Co-Founder & Chief Executive
Officer, Axial Biotherapeutics



Nikole Kimes
Co-Founder & Vice President, Siolta
Therapeutics



Ilana Brito
Assistant Professor, Department of
Biomedical Engineering, Cornell
University



Peter Christey
Chief Executive Officer,
General Automation Lab
Technologies



Melanie Gareau
Assistant Professor, University of
California, Davis



Gonca Pasin
Executive Director, California Dairy
Research Foundation [SESSION
CHAIR]



Cara Welch
Senior Advisor, Office of Dietary
Supplement Programs, CFSAN,
Food and Drug Administration
[Reserved]



Luis Vitetta
Director of Medical Research,
Medlab Clinical/ Professor,
University of Sydney, Australia



Maciej Chichlowski
Principal Scientist,
Mead Johnson Nutrition



Jennifer Boyd
Regulatory Manager Human
Health & Nutrition - US, Canada &
Latin America, Chr. Hansen



Brian Berg,
Associate Director, Global
Discovery R&D, Mead Johnson
Nutrition



Laurens Kruidenier
Senior Director, Head of GI
Immunology, Takeda
Pharmaceuticals



Erick Young
Director of External Innovation,
Research Beyond Borders Division
Boehringer Ingelheim



Monique Lacroix
Professor & Director, Research
Laboratories in Sciences, INRS-
Institut Armand-Frappier, Canada



Chris Callewaert
Postdoctoral Scholar, University of
California, San Diego/Founder of
"Dr. Armpit"



Dario Gutierrez
Immuno-Biology Lead, Merck
Research Laboratories [SESSION
CHAIR]



Arjan Narbad
Professor & Research Leader,
Institute of Food Research, UK



Bonnie Feldman
Digital Health Analyst and Chief
Growth Officer, DrBonnie360 – Your
Autoimmunity Connection
[SESSION CHAIR]



Mike Step
CEO
Ritter Pharmaceuticals

Also speaking:

Senior Representatives from: **Bio-Kult/Protexin, Second Genome, Capsugel, Metabolon, DNA Genotek, Lallemand Health Solutions, Winclove Probiotics, SynCo Bio Partners, NIZO Food Research BV**



Missed last year's congress?

Last year's Microbiome R&D and Business Collaboration saw Global Engage's popular annual meeting expand with a co-located Pro- and Prebiotics Congress. The congress which took place across two days in October saw over 350 industry and academic experts converge on La Jolla to examine the latest scientific developments in microbiome research, meet the latest companies moving into this area, and form the much necessary partnerships in order to translate research into effective therapeutics. Highlights included a first-class line-up of experts from scientific leaders such as Rob Knight and Rich Gallo to industry leaders Enterome and 4D Pharma which were mixed in with thought-provoking panel discussions on pharmaceutical involvement in the field, venture capital funding and a buzzing exhibition hall. The conference had a real global flavor with attendees arriving in from most continents and a with lunch offerings including kimchee, kefir and fermented mayonnaise; delegates left with not only the new contacts to progress their research and business but a balanced gut ecosystem!



"[The congress is] a very nice mixture of academia and industry...the perfect size to meet people"
LEO Innovation Lab

"The scientific content was excellent as were the networking opportunities"
DNA Genotek

"The networking with microbiome & pharma companies was excellent. The dual format made it convenient to get both types of information and meet people across disciplines."
Ritter Pharmaceuticals



86%

would be interested to attend in 2017

351 attendees last year



WHY NOT ALSO CHECK OUT:



**4th MICROBIOME FORUM:
EUROPE**

**3-4 APRIL 2017
AMSTERDAM**

Global Engage
Ltd

Sponsors 2017

Platinum Sponsor



Gold Sponsors:



Silver Sponsors



Exhibitors & Content Sponsors



Venue

To Be Confirmed

We are currently negotiating with a number of hotels in the San Diego area and further information will be released shortly

Last year the conference was held at the San Diego La Jolla Marriott. A discounted rate at the venue will be available through Global Engage once a venue has been finalized.

A range of accommodation to suit all budgets can be sourced locally. For more information, please contact Scott Taylor scott@globalengage.co.uk



Agenda: Day One – Thursday, 2 November 2017

8.00-8.45	Registration & Coffee		
8.45-8.50	Global Engage Welcome Address & Morning Chair's Opening Remarks		Global Engage Welcome Address & Morning Chair's Opening Remarks
	Gut Microbiota in Health & Disease		Probiotics Congress
8.50-9.30	Keynote Address: RESERVED: Rob Knight, Professor of Pediatrics and Computer Science & Engineering, University of California, San Diego	Keynote Address: RESERVED: Cara Welch, Senior Advisor, Office of Dietary Supplement Programs, CFSAN, Food and Drug Administration	
9.30-9.55	Engineering the Microbiome Synthetic biology is enabling more precise strategies for modulating the human microbiome, both in terms of adding microbes with artificial functions as well as deleting targeted microbiome members. Here we will discuss technology platforms for microbiome engineering and clinical applications being pursued. CONFIRMED: Timothy Lu, Associate Professor in the Department of Electrical Engineering and Computer Science, MIT	Probiotic and Dietary Supplement Regulatory Concerns CONFIRMED: Jennifer Boyd, Regulatory Manager Human Health & Nutrition - US, Canada & Latin America, Chr. Hansen	
9.55-10.25	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk		Sponsored Presentation: Sabinsa, founded in 1988, provides alternative and complementary natural products for human nutrition and well-being. Sabinsa has pioneered the introduction of more than 100 standardized botanical extracts, and privately funded clinical studies in conjunction with prestigious institutions in support of these products. Globally positioned with 1,000 people working in manufacturing and distribution facilities, and 100 full-time scientists conducting on-going research in India and the United States. Ingredients by Sabinsa are Kosher and Halal certified. CONFIRMED: Anurag Pande, Vice President – Scientific Affairs, Sabinsa Corporation  SABINSA CORPORATION
10.25-11.35	Morning Refreshments Poster Presentation Sessions & Scheduled One-to-One Meetings		
	Gut Microbiota in Health & Disease	R&D Outside the Gut Session Chair: Lada Rasochova, CEO, Dermal Inc.	Probiotics Congress
11.35-12.00	Microbiome and Drug Development RESERVED: Senior Representative, Janssen Microbiome Institute	The Cutaneous Microbiome in Immune Mediated Skin Disorders: Promises and Challenges • Aberrations in the cutaneous microbiome have been implicated in the pathogenesis of chronic, immune mediated skin diseases. • Techniques that restore microbial homeostasis or diversity of the cutaneous microbiota have been proposed as therapeutic options. • There are real challenges, but also opportunities, in designing and executing studies that involve the cutaneous microbiome. CONFIRMED: Adela Rambi Guanco Cardones, Assistant Professor of Dermatology, Duke University	Resetting microbiota by <i>Lactobacillus reuteri</i> inhibits Treg deficiency-induced autoimmunity Regulatory T-cell (Treg) deficiency causes lethal, CD4 ⁺ T cell-driven autoimmune diseases. Foxp3 ⁺ Treg deficiency results in gut microbial dysbiosis over the lifespan of scurfy (SF) mouse. Remodeling microbiota with <i>L. reuteri</i> prolonged survival and reduced multi-organ inflammation in SF mice. <i>L. reuteri</i> changed the metabolomic profile with a major effect was to restore levels of the purine metabolite inosine. Feeding inosine prolonged life and inhibited multi-organ inflammation by reducing Th1/Th2 cell associated cytokines. The inhibition of inosine on the differentiation of Th1 and Th2 cells <i>in vitro</i> depended on adenosine A _{2A} receptors, which were also required for the efficacy of inosine and of <i>L. reuteri</i> <i>in vivo</i> . The study reveals that the <i>Lactobacilli</i> -microbiota-inosine-A _{2A} axis might represent a potential avenue for combatting autoimmune diseases mediated by Treg dysfunction. CONFIRMED: Yuying Liu, Associate Professor, Department of Pediatrics University of Texas

12.00-12.25	How Seres Therapeutics is Utilizing the Microbiome for Human Health CONFIRMED: Lata Jayaraman, Senior Director, Seres Therapeutics	Skin Immunology and Acne CONFIRMED: Jenny Kim, Professor of Clinical Medicine, University of California, Los Angeles	The effect of a novel probiotic on metabolic biomarkers in adults with prediabetes and recently diagnosed type 2 diabetes mellitus: a randomized controlled trial - T2DM is characterised by persistent low-grade inflammatory responses associated with the development of insulin resistance. - Variations in the type, diversity and metabolic capacity of the gastrointestinal microbiota have been shown to alter metabolic and inflammatory pathways within the host by shifting energy balance and storage and promoting metabolic endotoxaemia. - An evidence-based multi-species probiotic formulation was investigated postulated to shift the GI microbiome from a disease-prone to a balanced state and in turn improving metabolic markers associated with T2DM. CONFIRMED: Luis Vitetta, Director of Medical Research, Medlab Clinical/ Professor, University of Sydney, Australia
12.25-12.50	Bugs as Drugs: Creating Microbiota Based Drugs with Quality Science Research and business around the microbiome continues to rapidly expand. There are currently many institutions and companies looking at various ways to utilize bugs as drugs. More science and quality parameters are being developed to create, manufacture and commercialize these new and unique medicines to treat various diseases of the microbiome. Microbiota Restoration Therapy (MRT) is one example of a new and novel way to provide bugs as drugs utilizing Science and Quality. CONFIRMED: Lee Jones, Founder, President & Chief Executive Officer, Rebiotix	The Promise and Challenge of Applying Microbiome Research to Drug Discovery - Commensals and inflammation - Appreciating cause and effect - Practical applications CONFIRMED: Susan Smith, Head of Immunology, Dermatology Therapy Area, GlaxoSmithKline	Development of <i>Lactobacillus reuteri</i> as a therapeutic delivery platform One of the long-term goals of the Van Pijkeren Laboratory is to develop probiotic bacteria as therapeutic delivery vehicles. The health-promoting phenotypes, the long history of safe consumption, combined with the ability to survive passage through the mammalian gastrointestinal tract, make select probiotic strains excellent candidates to deliver therapeutics <i>in situ</i>. Our model organism is <i>Lactobacillus reuteri</i> (Lr), a gut symbiont with well-characterized probiotic characteristics. Lr is also one of few probiotic strains for which high-throughput genome editing tools are available. We will discuss the development of various genetic tools for use in Lr, and its applications towards the development of a therapeutic delivery vehicle. CONFIRMED: Jan Peter van Pijkeren, Assistant Professor, Department of Food Science, University of Wisconsin-Madison
12.50-1.05	Company Showcase For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk	Company Showcase For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk	Company Showcase For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk
1.05-2.05	Lunch		
2.05-2.35	Sponsored Presentation: Winclove Probiotics is specialized in research, development, and production of probiotic formulations for over 25 years. We closely collaborate with business partners, research institutes and university hospitals to develop indication-specific multispecies probiotics. Our expertise allows us to constantly develop new innovative probiotics substantiated by scientific research. We offer probiotic therapies for the traditional GI therapeutic indications as well as more innovative areas, such as; women's health, mental health and upper respiratory tract infections. Our products are sold by our business partners under private label worldwide.  CONFIRMED: Senior Representative, Winclove Probiotics	Panel Discussion: The Microbiome: An Opportunity for Smarter Cosmetics - Impact of the microbiome on traditional products, and on marketing campaigns - Integrating smart bacteria into products - Impact of products on commensal skin flora - Accounting for diversity and age - Health claim substantiation and regulatory considerations CONFIRMED: Jasmina Aganovic, President, Mother Dirt Trevor Steyn, CEO, ESSE Probiotic Skincare Chris Callewaert, Postdoctoral Scholar, University of California, San Diego/Founder of "Dr. Armpit"	Sponsored Presentation: Capsugel designs, develops and manufactures a wide range of innovative dosage forms for the biopharmaceutical and consumer health & nutrition industries. Our unique combination of science, engineering, formulation and capsule expertise enables our customers to optimize the bioavailability, targeted delivery and overall performance of their products. We partner with more than 4,000 customers in over 100 countries to create novel, high-quality and customized solutions that align with our customers' evolving needs and benefit patients and consumers.  CONFIRMED: Senior Representative, Capsugel

2.35-3.00	How Takeda is Utilizing the Microbiome for GI Disorders CONFIRMED: Laurens Kruidenier, Senior Director, Head of GI Immunology, Takeda Pharmaceuticals	Synthetic Biology Approach to Treatment of Skin Issues via Microbiota - Exploring possible deficiencies in microbiome-centric strategies for treating inflammatory issues - Reviewing similarities between the gut and skin and how we can translate microbiome therapies accordingly - Discussing use of the microbiota to optimize topical delivery of biotherapeutics CONFIRMED: Thomas Hitchcock, Founder and Chief Executive Officer, Xyrobe Therapeutics Inc.	Preservation of the vitality of probiotics during processing and protection against environmental stress by encapsulation - Drying of microbial starter cultures and probiotics for preservation and storage purposes can be optimized in terms of survival - The reduction of drying times can be achieved by microwave technology applied to accelerate freeze drying and vacuum drying, without compromising on degree of survival and activity upon rehydration. The key insights of recent works are currently being applied in drying of the human gut microbiome and representative surrogates. The dried material can be used as part of a concept of treatment of patients with a disturbed microbiome. - Sensitive probiotics can be protected against outer environmental and processing stress factors in very dense protein encapsulation matrices CONFIRMED: Ulrich Kulozik, Professor & Chair of Food Process Engineering and Dairy Science, Technical University of Munich, Germany
3.00-3.25	Modification of the Pediatric Gut Microbiome: Past, Present and Future - The role of the pediatric gut microbiome in health and disease - Effective ways to modify the gut microbiome - Fecal microbial transplant and how it impacts the gut microbiome CONFIRMED: Sonia Michail, Professor of Clinical Pediatrics, University of Southern California	Challenges in developing a Live Biologic Therapeutic - Strain selection - Intellectual Property - Rx vs DTC - Manufacturing - Formulation - Regulatory strategy - Clinical Trial CONFIRMED: Emma Taylor, Chief Executive Officer & Co-Founder, Naked Biome	Screening Gut Microbiota Strain Libraries My lab has developed a culturomics method to develop gut microbiota strain libraries in a high-throughput manner and to screen them for beneficial properties CONFIRMED: Joy Scaria, Assistant Professor, Department of Veterinary & Biomedical Sciences, South Dakota State University
3.25-3.40	Company Showcase: SynCo Bio Partners, a world leading GMP contract manufacturer of live microbial products, has a proven technical and quality track record in the bulk drug substance manufacturing and aseptic filling and lyophilization of a broad range of live microbial products. Located in Amsterdam, approved by several international authorities and with over 20 years GMP manufacturing experience, SynCo supports many clients in bringing their live microbial products through clinical development and safely to the patient.  CONFIRMED: Senior Representative, SynCo Bio Partners	Company Showcase For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk	Company Showcase:  The experts in probiotics CONFIRMED: Senior Representative, Bio-Kult/Protexin
3.40-4.30	Afternoon Refreshments Poster Presentations & Networking Meetings		

	Session Chair: Alex White, Senior Conference Producer, Global Engage Ltd.	Session Chair: Bonnie Feldman, Digital Health Analyst and Chief Growth Officer, DrBonnie360 – Your Autoimmunity Connection	Session Chair: William Baird, Director, Global Engage Ltd.
4.30-4.55	<u>INDUSTRY & INVESTMENT ROUNDTABLES</u> 1. Malcolm Kendall, Founder & CEO, Microbiome Insights MICROBIOME INVESTMENT AND FINANCING 2. Colleen Cutcliffe, CEO & Co-Founder, Whole Biome Inc. BALANCING IP AND REGULATORY RISK IN THE MICROBIOME 3. Erick Young, Director of External Innovation, Research Beyond Borders Division, Boehringer Ingelheim AWAITING TITLE: COLLABORATIONS WITH PHARMA 4. Mark Smith, Chief Executive Officer, Finch Therapeutics AWAITING TITLE	Oral Microbiome & Its Targeted Modulation The talk will cover the basic biology of oral microbiome including its composition, spatial location, social interactions, as well as our latest efforts on developing novel diagnostic and therapeutic tools to reengineering oral microbiome. CONFIRMED: Wenyuan Shi, Professor and Chair of Oral Biology, UCLA Schools of Medicine and Dentistry/CSO, C3 Jian Inc.	<u>INDUSTRY & INVESTMENT ROUNDTABLES</u> 5. Mary Ellen Sanders, Executive Science Officer, International Scientific Association for Probiotics and Prebiotics CONSUMERS DESERVE TO KNOW WHAT'S IN THE BOTTLE • Taking probiotic product verification to the next level • What options are out there? • What are the roadblocks? • When can consumers expect to see third party verification that probiotic products are what they claim? 6. Probiotic Screening Methods Moderator: 7. Probiotics and Prebiotics Products Moderator:
4.55-5.20		Functional Signatures of Dysbiosis in the Oral Microbiome Periodontitis is a polymicrobial biofilm-induced inflammatory disease that affects 743 million people worldwide. The current model to explain periodontitis progression proposes that changes in the relative abundance of members of the oral microbiome lead to dysbiosis in the host-microbiome crosstalk and then to inflammation and bone loss. However, it is only poorly understood how a dysbiotic microbiome initially interacts with the host to dysregulate its physiology leading to inflammation and pathological bone resorption. Even less known is how dysbiosis arises in the first place and whether it is a cause or a consequence of the disease process. Using combined metagenome/metatranscriptome analysis of the subgingival microbiome in progressing and non-progressing sites we have characterized the distinct molecular signatures of periodontitis progression. CONFIRMED: Jorge Frias-Lopez, Associate Professor, Department of Oral Biology, University of Florida	
5.20	Day One Close		
6.30-7.30	Drinks Reception at location TBC in La Jolla If you would like to sponsor the drink's reception please contact Gavin Hambrook at gavin@globalengage.co.uk		

Agenda: Day Two – Friday, 3 November 2017

8.00-8.25	Networking Meetings & Coffee		
8.25-8.30	Microbiome Forum	Probiotics Congress	
	Morning Chair's Opening Remarks Session Chair: Dario Gutierrez, Immuno-Biology Lead, Merck Research Laboratories	Morning Chair's Opening Remarks Session Chair: Gonca Pasin, Executive Director, California Dairy Research Foundation	
8.30-8.55	Awaiting Presentation Title RESERVED: Senior Representative, Food and Drug Administration	Digital PCR for Strain-Specific Enumeration of Probiotics CONFIRMED: Buffy Stahl, Genomics and Microbiome Science Leader, DuPont Nutrition & Health	
8.55-9.35	Keynote Address: The Gut-Microbiome-Brain Connection in Neurological Disease CONFIRMED: Sarkis Mazmanian, Louis & Nelly Soux Professor of Microbiology, California Institute of Technology	Keynote Address: Health-Promoting Properties Encoded within Fermented Food Microbiota - Putative health-promoting attributes associated of fermented foods - Sequencing based insights into health-promoting genes encoded within such foods - How to harness this knowledge? CONFIRMED: Paul Cotter, Head of Department, Food Biosciences, Teagasc, and PI, APC Microbiome Institute, Republic of Ireland	
9.35-9.40	Gut Microbiota in Health & Disease Session Chair: Dario Gutierrez, Immuno-Biology Lead, Merck Research Laboratories	Session Chair:	Probiotics Congress Session Chair: Gonca Pasin, Executive Director, California Dairy Research Foundation
9.40-10.10	Sponsored Presentation: Ritter Pharmaceuticals develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease  CONFIRMED: Mike Step, CEO, Ritter Pharmaceuticals	Sponsored Presentation: Enabling Access to Microbes - A Next Generation Platform for Exploring the Microbiome General Automation Lab Technologies, Inc. (GALT) is transforming microbiome research and microbial product development with our innovative high throughput microbiology research platform. There is a critical need for new improved research tools to drive our understanding of complex microbial populations and their interactions with their environment. GALT is currently focused on solving two core problems in microbiology: 1) cultivating target microbes that are difficult or impossible to cultivate using current technologies, and 2) screening microbiomes, strain collections or engineered populations of microbes for target phenotypes or metabolites.  CONFIRMED: Peter Christey, CEO, General Automation Lab Technologies	Sponsored Presentation: Lallemand Health Solutions offers a full line of ready-to-market probiotic formulas such as Lacidofil®, Probiokid®, Probio'Stick®, Protecflor®, and can also design, develop and produce custom formulations based on the documented Rosell, Harmonium, or Lafti® strains. From lab to shelf, LHS controls the overall manufacturing process of its products. Our probiotic strains and formulas are produced in-house in one of our many available bacteria production facilities at LHS to ensure customers are receiving the highest quality standard of probiotic formulations.  CONFIRMED: Senior Representative, Lallemand Health Solutions
10.10-11.20	Morning Refreshments Poster Presentation Sessions & Scheduled One-to-One Meetings		

11.20-11.45	Panel Discussion: The 'Oncobiome' - Human Microbiome and Cancer Therapies - How does the microbiome influence/protect from cancer development? - Microbiome interactions with cancer therapies - How does the microbiome impact cancer development in sites outside the gut? - Manipulating the microbiome to improve prognosis and treatment - Development of immune-microbiome cancer therapies	The Impact of Milk Oligosaccharides on Brain-Gut-Microbiota Axis CONFIRMED: Maciej Chichlowski, Principal Scientist, Mead Johnson Nutrition	The Interplay of Indigenous Microbiota and Transient Probiotic Species Focused almost exclusively on the microbiota present in the colon, most of the attention in the pro/prebiotic sector has involved either the introduction of probiotic species with the hope of transient population or feeding select microbiota with some sort of prebiotic soluble fiber. Here, we discuss the role of indigenous (autochthonous) bacterial species with respect to foreign (allochthonous) organisms, and how the interplay may be connected to states of disease in the colon and distal esophagus. CONFIRMED: Lee Madsen II, Vice President & Chief Science Officer, ISOThrive
11.45-12.10	CONFIRMED: Jackie Papkoff, Senior Vice President Research, Evelo Biosciences Marina Walther-Antonio, Assistant Professor of Surgery, College of Medicine, Mayo Clinic Invite to: Senior Representatives x3	Gut Feelings: The developing microbiota-gut-brain axis in mice - Intestinal dysbiosis may be leading to changes in mood and behaviour - Probiotics may restore the microbiota and prevent dysfunction of the microbiota-gut-brain axis - Identifying the developmental window during which the microbiota-gut-brain axis is vulnerable to long term detrimental impacts CONFIRMED: Melanie Gareau, Assistant Professor, University of California, Davis	PreForPro: A phage-based therapy for modifying the gut microbiota - Background on phage therapy and potential use as a dietary supplement - Description of the PreForPro clinical trial - Interpretation of phage-induced changes to the gut microbiota and in physiological clinical parameters CONFIRMED: Tiffany Weir, Associate Professor, Colorado State University
12.10-12.40	Sponsored Presentation: Second Genome Solutions, the premier microbiome profiling provider, has completed over 350 microbiome studies to date for researchers in academia, and pharma/biotech, nutrition and skincare companies. Our Microbiome Discovery Platform of validated analysis and bioinformatics methods has been expertly developed to deliver the most complete and reliable microbiome insights.  SECOND GENOME THE MICROBIOME COMPANY CONFIRMED: Senior Representative, Second Genome	Sponsored Presentation: The growing world population needs better food: healthier, tastier, more affordable and produced more sustainably. We know better food is essential for better health. Our passion is accelerating innovations together with our customers, applying our combined expertise in bacteria, proteins and processing. Together we deliver sustainable solutions for better food and health.  CONFIRMED: Senior Representative, NIZO Food Research BV	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk
12.40-12.55	Company Showcase: DNA Genotek Inc., a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), provides high-quality biological sample collection products and end-to-end services for human genomics, microbiome and infectious disease applications. Our OMNIgene product line immediately stabilizes microbiota, ensuring an unbiased 'snapshot' of the microbial community is maintained. Kits for stool, oral, vaginal and animal sampling are available. We also offer GenoFIND™, a complete suite of genomics and microbiome services including sample processing, wet lab and bioinformatics analysis.  CONFIRMED: Senior Representative, DNA Genotek	Company Showcase For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk	Company Showcase For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk
12.55-1.55	Lunch & Networking Meetings		

1.55-2.20	Exploring the structure and function of the gut microbiome in multiple sclerosis • Largest study in MS microbiome under way • Preliminary data shows moderate but consistent dysbiosis in MS patients • Bioinformatics, in-vitro and in-vivo studies suggest the MS gut microbiome plays a role in disease pathogenesis CONFIRMED: Sergio Baranzini, Professor, Department of Neurology, University of California, San Francisco	Patenting Microbiome Therapeutics • Categories of microbiome therapeutics • Patent prosecution and the 101 hurdle • Strategies for patenting microbiome therapeutics CONFIRMED: Erik Spek, Vice President – Head of Intellectual Property, Vedanta Biosciences	How Mead Johnson Nutrition is Leveraging Prebiotics for Improved Health CONFIRMED: Brian Berg, Associate Director, Global Discovery R&D, Mead Johnson Nutrition
2.20-2.45	Transmissible Components in the Microbiome CONFIRMED: Ilana Brito, Assistant Professor, Department of Biomedical Engineering, Cornell University	Next Generation Microbial Therapeutics - Transforming the Therapeutic Landscape of Asthma and Atopy Siolta Therapeutics is an early-stage biotech pursuing next generation microbial therapeutics aimed at the prevention and treatment of inflammatory diseases. Our current research and development is focused on the rational design of a mixed-species therapeutic microbial consortium to treat airway inflammation. We are concurrently working towards a future in which the microbiome can help drive patient stratification and tailored microbial therapeutics. CONFIRMED: Nikole Kimes, Co-Founder & Vice President, Siolta Therapeutics	Cancer Preventive Effect of a Probiotic Fermented Milk containing <i>L. Acidophilus</i> CL1285, <i>L. Casei</i> LBC80R, <i>L. Rhamnosus</i> CLR2 The potential of fermented milk containing three Lactobacillus strains on colon carcinogenesis was investigated. Results showed that rats supplemented with probiotic formula had significantly lowered the count of aberrant crypt (AC) and the number of aberrant crypt foci as compared to the control group ($p \leq 0.05$). Rats administered with the fermented milk pellet were able to significantly ($p \leq 0.05$) induce the activity of quinone reductase as compared to the control group. Rats administered with the fermented milk showed a significant lower activity of β-glucuronidase ($p \leq 0.05$), a reduced activity of β-glucosidase and an induction of the activity of glutathione S-transferase ($p \leq 0.05$). These results indicate that the probiotic bacteria and the metabolite release during the fermentation process could prevent colorectal carcinogenesis. CONFIRMED: Monique Lacroix, Professor & Director, Research Laboratories in Sciences, INRS-Institut Armand-Frappier, Canada
2.45-3.15	Sponsored Presentation: Metabolon, Inc. is the world's leading metabolomics company. Its proprietary platforms are accelerating research and product development for more than 600 clients across the pharmaceutical, biotechnology, consumer products, agriculture, and nutrition industries. Founded in 2000 and headquartered in Research Triangle Park, North Carolina, the company has conducted more than 5,000 independent and collaborative studies, resulting in over 500 publications.  CONFIRMED: Senior Representative, Metabolon	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk
3.15-4.00	Panel Discussion: The Business of the Microbiome • Building a business strategy and model • Structuring successful collaborations • Riding the wave on fundraising CONFIRMED: • Mohan Iyer, Chief Business Officer, Second Genome • Henry Rath, Vice President of Business Development, Seres Therapeutics • David Donabedian, Co-Founder & CEO, Axial Biotherapeutics	Microbiome Signature in Endometrial Cancer • Endometrial microbiome can be used to identify patients with endometrial cancer • Vaginal microbiome can be used as a proxy of the endometrial microbiome to identify patients with malignancy • In search of a microbiome predictor. Can we identify patients on a carcinogenic path? CONFIRMED: Marina Walther-Antonio, Assistant Professor of Surgery, College of Medicine, Mayo Clinic	Awaiting Presentation Title CONFIRMED: Arjan Narbad, Professor & Research Leader, Institute of Food Research, UK

4.00-4.25	Afternoon Refreshments		
4.25-4.50	Examining the Impact of Stress on the Gut Microbiome CONFIRMED: Michael Bailey, Associate Professor, Pediatrics, The Ohio State University	Vaginal Microbiome and Women's Health CONFIRMED: Peter Lee, Founder & Executive Chairman, Osel inc.	Awaiting Presentation Title Topic: Prebiotics and Dietary Fiber RESERVED: Senior Representative, Kellogg Company
4.50-5.15	Using Microbiome Analytics to Drive Development of Interventions • Generation of tools to analyze next generation sequencing, metabolite data and host-microbiome interactions data • Integrating these with pathway predication tools to generate a comprehensive view of an individual's microbiome and identify novel targets • Testing interventions and generating new data to drive improved development of diagnostics and interventions CONFIRMED: Colleen Cutcliffe, CEO & Co-Founder, Whole Biome Inc.		
5.15	Conference Close		

For further information please contact Steve Hambrook, Conference Director,

steve@globalengage.co.uk